Similar to the findings of other studies in the STEP trial program 7,27 , exploratory outcomes showed that in the semaglutide group 80% of participants with prediabetes at baseline reverted to normoglycemia by the end of the trial (compared with 37% of those receiving placebo), while 99% of participants with normoglycemia at baseline maintained normoglycemia at the end of the trial (compared with 86% with placebo)
10, 2025 from Pavli, P., Triantafyllidou, O., Kapantais, E., et al
Two of those are actionable on your end
3 If youre prescribed medication, a FWD Care pharmacy partner can deliver in 3 days or less
Food and Drug Administration (FDA) announced a semaglutide warning label update on September 22, 2023, warning that Ozempics warning label would be updated to include certain gastrointestinal side effects on September 22, 2023
PlexusDx supports this personalized approach by helping patients and providers understand the biological context underlying treatment decisions